Abstract
Human cartilage glycoprotein-39 (HC gp-30) is a secretory protein of several types of cells including chondrocytes. It has been suggested to be a laboratory index of joint damage. Thirty-two patients with systemic sclerosis (SSc) and 22 age-matched controls were investigated. An increased serum HC gp-39 level was shown in SSc patients and was found to correlate with inflammatory indices. There was no correlation with modified Rodnan score, joint involvement, or duration of symptoms of SSc. The obtained results indicate for possible relationship of HCgp-39 to inflammation but do not suggest determination of HC gp-39 as clinically applicable index of articular involvement in SSc patients.
This is a preview of subscription content, log in via an institution to check access.
References
Blocka KLN (2004) Musculoskeletal involvement in systemic sclerosis. In: Clements PJ, Furst DE (eds) systemic sclerosis. Lippincott Williams and Wilkins, Philadelphia, pp 249–260
Hakala BE, White C, Recklies AD (1993) Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 268:25803–25810
Wcislo-Dziadecka D, Kotulska A, Kucharz EJ (2005) Human cartilage glycopritein-39, structure, biological role and application in diagnostics. Reumatologia 43:147–153, in Polish
Johansen JS, Kirwan JR, Price PA, Sharif M (2001) Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand J Rheumatol 30:297–304
Wcislo-Dziadecka D, Kotulska A, Brzezinska-Wcislo L, Kucharz EJ, Lis-Swiety A, Kaminska-Winciorek G (2009) Serum human cartilage glycoprotein-39 levels in patients with systemic lupus erythematosus. Pol Arch Med Wewn 119:785–788
Johansen JS, Cintin C, Jorgensen M, Kamby C, Price PA (1995) Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 31A:1437–1442
La Montagna G, D'Angeli S, Valentini G (2003) Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease. J Rheumatol 30:2147–2151
Nordenbaeck C, Johansen JS, Halberg P, Wiik A, Garbarsch C, Ullman S, Price PA, Jacobsen S (2005) High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheum 34:293–297
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590
Vos K, Steenbakkers P, Miltenburg AMM, Bos E, Van de Heuvel MW, Van Hogezand RA, De Vries RRP, Breedveld FC, Boots AMH (2000) Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 59:544–548
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wcislo-Dziadecka, D., Kotulska, A., Brzezińska-Wcislo, L. et al. Serum human cartilage glycoprotein-39 in patients with systemic sclerosis: relationship to skin and articular manifestation. Clin Rheumatol 29, 933–935 (2010). https://doi.org/10.1007/s10067-010-1462-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-010-1462-y